Study description: STRIVE (Study of TYSABRI in Early Relapsing-RemItting Multiple Sclerosis in Anti-JCV Antibody NegatiVE Patients) was a 4-year, multicenter, observational, open-label, single-arm study conducted in the United States. Patients were anti-JCV antibody negative ≤6 months prior to screening or at baseline and were prescribed natalizumab 300 mg IV ≤3 years after RRMS diagnosis; 47% of patients (n=105) completed all 4 years on TYSABRI, while 41% (n=91) discontinued TYSABRI and 30% (n=67) withdrew prior to Year 4.
bp values are based on unadjusted logistic regression models. Patients with NEDA status available during both the first and fourth years are included.
The STRIVE study was funded by Biogen.